linjc16/ctgov huggingface dataset:
Development and Validation of a Risk Prediction Model for Preoperative Frailty in Elderly Patients With Colorectal Cancer

Study Overview
=================
Brief Summary
-----------------
Fried Scale and its related scales were used to analyze the status and risk factors of preoperative frailty in elderly patients with colorectal cancer. R software was used to construct a risk prediction model for preoperative frailty in elderly patients with colorectal cancer, and its validity and stability were verified in clinical practice.

Official Title
-----------------
Development and Validation of a Risk Prediction Model for Preoperative Frailty in Elderly Patients With Colorectal Cancer

Conditions
-----------------
Colorectal Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients who met the diagnostic criteria of colorectal cancer in Chinese Guidelines for Diagnosis and Treatment of Colorectal Cancer 2020 Edition and underwent surgery; patients aged ≥60 years old ; patients who are clearly conscious, able to understand instructions, communicate normally, and complete the physical activity ability test without the assistance of others; patients who gave informed consent and volunteered to participate in the study. Exclusion Criteria: patients with limb joint disease and lower limb pain; patients with serious heart, liver, kidney diseases could not complete the test; patients with visual impairment and hearing impairment; patients with a history of mental illness or drug dependence; taking antidepressants, levodopa/carbidopa, donepezil hydrochloride and other drugs ; patients who received preoperative radiotherapy and chemotherapy; Patients with hypothyroidism, Parkinson's disease, stroke and other diseases.

Ages Eligible for Study
-----------------
Minimum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Status of frailty | Status of frailty will be assessed by Fried Scale | 1 day |
Selective Activation of the Infraspinatus During External Rotation Exercises in Participants With Rounded Shoulder Posture

Study Overview
=================
Brief Summary
-----------------
The purpose of this prospective, cross-sectional study was to evaluate the selective activation of the infraspinatus during external rotation exercises in participants with rounded shoulder postures and compare the different exercise positions. The fifteen (7 males and 8 females) participants with rounded shoulder posture were recruited for this study. The EMG activations of the middle trapezius, posterior deltoid and infraspinatus muscles in the dominant limb were recorded during exercises in standing external rotation (SER), side-lying position (SDER), scapular plane (SPER) and muscle architecture-based (MABER) positions.

Official Title
-----------------
Selective Activation of the Infraspinatus During External Rotation Exercises in Participants With Rounded Shoulder Posture: Comparison of 3 Common Exercises and Muscle Architecture-Based Exercise

Conditions
-----------------
Shoulder Disease

Intervention / Treatment
-----------------
* Device: The EMG activations


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: without shoulder pain, totally able to perform overhead activities with no pain or discomfort, without a history of shoulder injuries with rounded shoulder posture Exclusion Criteria: a history of shoulder muscle injury bone fractures in shoulder region luxation or subluxation cervical dysfunction radiating to upper limbs neurologic or musculoskeletal disorders that would prevent shoulder external rotation in the testing postures.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: The EMG activations|The EMG activations of the middle trapezius, posterior deltoid and infraspinatus muscles in the dominant limb were recorded during exercises in standing external rotation (SER), side-lying position (SDER), scapular plane (SPER) and muscle architecture-based (MABER) positions|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The EMG activations of the middle trapezius, posterior deltoid and infraspinatus muscles in the dominant limb | The EMG activations of the middle trapezius, posterior deltoid and infraspinatus muscles in the dominant limb were recorded during exercises in standing external rotation (SER), side-lying position (SDER), scapular plane (SPER) and muscle architecture-based (MABER) positions | 4 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Infraspinatus, Muscle architecture, Rounded Shoulder Posture, Superficial EMG
The Effect of Blood Tests Performed Within the Routine Protocol in the Surgical Intensive Care Unit on Hemoglobin Levels

Study Overview
=================
Brief Summary
-----------------
Examination of blood samples is inevitable in intensive care units. Routine blood samples can be an important cause for anemia. In this study, we aimed to examine how our blood collection routine affects hemoglobin values.

Detailed Description
-----------------
Blood tests for follow-up and treatment are widely used in intensive care units (ICU). Although its etiology is very diverse, phlebotomy performed due to frequent laboratory tests is among the preventable causes of anemia. In this observational study, blood tests performed on patients treated in intensive care units followed up in our clinic between 01.April.2023 - 31.May.2023 (2 months) will be examined. Patients' age, presence of additional disease, indication for admission to the unit, Acute Physiology and Chronic Health Assessment II (APACHE II), Sequential Organ Failure Assessment (SOFA) and Glasgow coma scale (GCS), hemoglobin values will be recorded. The daily blood test will record the amount of blood drawn for analysis (in milliliters), where it was taken from (peripheral, central venous or arterial catheter), and the amount of excess blood. Statistical analysis will be performed in terms of patient characteristics, routine blood volumes and development of anemia.

Official Title
-----------------
The Effect of Blood Tests Performed Within the Routine Protocol in the Surgical Intensive Care Unit on Hemoglobin Levels

Conditions
-----------------
Anemia

Intervention / Treatment
-----------------
* Behavioral: Drawn Blood Volume


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients followed in the intensive care unit for more than 48 hours, ≥18-year-old Exclusion Criteria: Patients not followed up by our clinic,≤18-year-old

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Drawn Blood Volume|Hemoglobine Changes|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of blood volume drawn for daily routine in intensive care | Daily routine blood test and blood volume determination in intensive care patients | 2 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Anemia | Evaluation of how daily routine blood drawn affects patients' hemoglobin values in intensive care patients | 2 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Intensive care unit, Routine blood sample, Overdrawn
Ultrasonic Evaluation of Carbon Dioxide Laser Effects on Patients With Genitourinary Syndrome

Study Overview
=================
Brief Summary
-----------------
The aim of the study was to evaluate the efficacy of vaginal Carbon Dioxide Laser treatment in patients with Genitourinary Syndrome of Menopause on the improvement of Vulvovaginal Atrophy (VVA) and stress urinary incontinence (SUI) by objective parameters and in particular to assess the ultrasound measurement of specific vaginal parameters in order to evaluate a new objective tool of assessment.

Official Title
-----------------
Ultrasonic Evaluation of Carbon Dioxide Laser Effects on Patients With Genitourinary Syndrome

Conditions
-----------------
Genitourinary Syndrome of Menopause

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age <75 years, menopause (naturally, pharmacologically or surgically induced, at least 12 months) Negative Papanicolaou test (PAP) performed within 12 months before enrolment. and one of the following: Presence of vulvovaginal atrophy [vaginal health index (VHI) < 15] Initial Urinary Incontinence based on patient history = 1 (according to the Stamey incontinence score of Stress Urinary Incontinence - min. 0 = no incontinence, max. 3 = severe incontinence) Standardized stress provocation test Exclusion Criteria: Age >45 years The presence of vaginal lesions (active or in the previous 30 days). genitourinary tract infection. abnormal uterine bleeding. use of hormone replacement therapy up to 6 months before enrolment. history of photosensitivity disorder or use of photosensitizing drugs. genitals prolapse (grade II - III according to the Pelvic Organ Prolapse Quantification) a serious or chronic condition that could interfere with study compliance.

Ages Eligible for Study
-----------------
Minimum Age: 45 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluating the effectiveness of Carbon Dioxide Laser in patients with genitourinary syndrome of menopause in terms of the improvement in a specific vaginal ultrasonographic parameters | To evaluate the primary outcome, we examined the following vaginal ultrasonographic parameters (by transvaginal probe), both before and after 3 vaginal Carbon Dioxide Laser applications: Thickness of the anterior vaginal walls (VWT) at the level of the introitus of the inferior vaginal third (expressed in millimeters); Thickness of the posterior VWT at the level of the introitus of the inferior vaginal third (expressed in millimeters). Positive outcomes are evidenced if thickness (expressed in millimeters) is increased after treatment in both anterior and posterior vaginal walls. | 4 months |
The Disease Severity In Patients With Psoriasis

Study Overview
=================
Brief Summary
-----------------
This observational study aims to evaluate new markers to predict disease activity in psoriasis. The main question is SGOT, SGPT, GGT, hs-CRP, and apo B related to disease severity in psoriasis.

Detailed Description
-----------------
Psoriasis patients who had signed an informed consent were assessed for PASI scores and 5 cc of blood was drawn for GGT, hs-CRP, and apo B examinations. A PASI score is a tool used to measure the severity and extent of psoriasis. PASI is an acronym for Psoriasis Area and Severity Index.

Official Title
-----------------
The Disease Severity In Patients With Psoriasis

Conditions
-----------------
Psoriasis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of Psoriasis Exclusion Criteria: Heart Failure Diabetes Mellitus Kidney Disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Gamma-Glutamyl Transferase | Gamma-Glutamyl Transferase was check in admission, reference range for adults is 5 to 40 U/L (units per liter) | only in admission | 
| Apolipoprotein B | Apolipoprotein B (ApoB) is the primary apolipoprotein and is the carrier for the following lipids: chylomicrons, low-density lipoprotein ( LDL), very low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), and lipoprotein. Unit used in mg/dL | only in admission | 
| High-sensitivity c-reactive protein | High-sensitivity C-reactive protein (hsCRP) is a marker of inflammation that predicts incident myocardial infarction, stroke, peripheral arterial disease, and sudden cardiac death. Unit used in mg/L | only in admission | 
| PASI | A PASI (The Psoriasis Area and Severity Index) score can range from 0 to 72 | only in admission | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Psoriasis, Psoriasis Area and Severity Index, Gamma-Glutamyl Transferase, CRP, Apolipoprotein B
Iodine Status After Intake of Sushi and Seaweed Salad

Study Overview
=================
Brief Summary
-----------------
Seaweed is becoming increasingly popular in the Western part of the world, especially sushi wrapped in nori and seaweed salad, also called wakame. There are limited data on the iodine content of different seaweed products in the Norwegian Food composition table. Furthermore, there is limited available research regarding in vivo bioavailability of iodine from seaweeds. The objective of this study is to assess whether iodine from a sushi meal (with nori, Porphyra spp), and a wakame salad (Undaria pinnatifida) has similar bioavailability as a potassium iodide reference supplement of similar iodine content.

Official Title
-----------------
Iodine Status at Several Time Points During 48 Hours After Intake of Sushi and Seaweed Salad- a Randomized Crossover Trial

Conditions
-----------------
Iodine Deficiency

Intervention / Treatment
-----------------
* Other: Sushi and wakame salad


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy women aged 18 to 40 years Exclusion Criteria: pregnant or lactating known thyroid disease or thyroid autoimmunity, planning to conceive, known kidney problems or kidney disease. women with coeliac disease could not participate due to possible gluten exposure from the wakame salad

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Sushi and wakame salad<br>231 microgram of iodine per serving | Other: Sushi and wakame salad<br>* One serving of mixed sushi and wakame salad<br>|
| Active Comparator: Potassium iodide supplement<br>225 microgram of iodine per tablet | Other: Sushi and wakame salad<br>* One serving of mixed sushi and wakame salad<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Urinary iodine concentration during 48 hours | Urinary iodine concentration after ingestion of the intervention/supplement during 48 hours by fixed time-intervals | 48 hours | 
| Bio-availability of iodine in the intervention/supplement | Calculation of the bio-availability of iodine in the intervention/supplement | 48 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
seaweed, bioavailability, iodine
Evaluation of the Patient's Experience in Medical Studies for Cholangiocarcinoma

Study Overview
=================
Brief Summary
-----------------
The main reason for conducting this research is to gain a better understanding of why some people with cholangiocarcinoma are not able to participate in or complete clinical trials. Historically, certain groups of people have been more likely to participate in clinical trials, but there hasn't been much research to understand why this is the case. The goal is to find out which aspects of a clinical trial may make it more difficult for patients to take part or see it through. The data will be evaluated through different demographic lenses and identify trends that could help improve the experience of future cholangiocarcinoma patients during clinical trials.

Official Title
-----------------
A Clinical Study Experiences of Cholangiocarcinoma Patients To Identify Trial Attributes Affecting Completion Rates For Specific Demographic Groups

Conditions
-----------------
Cholangiocarcinoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient is at least 18 years of age Participant has a diagnosis of Cholangiocarcinoma Patient has self-identified as planning to enroll in an interventional Cholangiocarcinoma clinical trial Patient must provide written informed consent Exclusion Criteria: No diagnosis of Cholangiocarcinoma confirmed Inability to perform regular electronic reporting Women who are pregnant, intend to become pregnant, or are lactating Patient does not understand, sign, and return consent form

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of patients who decide to enroll in a Cholangiocarcinoma Clinical Study. |  | 3 months | 
| Number of Cholangiocarcinoma patients who remain in clinical trial until completion. |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cholangiocarcinoma
Panomic Approach to Immune-Connected Assays in Small Cell Lung Cancer

Study Overview
=================
Brief Summary
-----------------
The scope of the PICASSO project is to apply an innovative patient-based pan-omic approach to immune-assays, that will include multi-omics tumour characterization (genome, proteome, transcriptome), blood immune-cells and cytokine profiling, serological screening for paraneoplastic autoantibodies, clinical and metabolic measurements. The PICASSO project is aimed to validate in real world population the predictive role of SCLC transcriptomic classification (particularly, I-SCLC subtype) and to explore correlations with dynamic changes in peripheral blood immunity. Additionally, investigators expected to validate the predictive/prognostic role of emerging new variables, including metabolic-induced meta-inflammation alterations and subclinical auto-immunity.

Official Title
-----------------
Panomic Approach to Immune-Connected Assays in Small Cell Lung Cancer

Conditions
-----------------
Small Cell Lung Cancer

Intervention / Treatment
-----------------
* Drug: Atezolizumab


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: histologically- or cytologically-documented extensive-stage SCLC to have received upfront treatment with Cisplatin/Carboplatin, etoposide and anti PD1/PD-L1 inhibitors No evidence of brain metastases at diagnosis ECOG PS 0-2 adult patients (aged ≥ 18 years) at diagnosis; signing of informed consent approved by the local Ethic Committee Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| ES-SCLC<br>ES-SCLC receiving upfront chemo-immunotherapy | Drug: Atezolizumab<br>* Upfront chemo-immunotherapy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PFS | Time from treatment start until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months | Up to 60 months | 
| OS | Time from treatment start to the date of death from any cause, assessed up to 60 months | Up to 60 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
sclc, immunotherapy